Objective-The ability of HDL (high-density lipoprotein) to promote macrophage cholesterol efflux is considered the main HDL cardioprotective function. Abdominal aortic aneurysm (AAA) is usually characterized by cholesterol accumulation and macrophage infiltration in the aortic wall. Here, we aim to evaluate the composition of circulating HDL particles and their potential for promoting macrophage cholesterol efflux in AAA subjects. Approach and Results-First, we randomly selected AAA and control subjects from Spain. The AAA patients in the Spanish cohort showed lower plasma apoA-I levels concomitantly associated with low levels of plasma HDL cholesterol and the amount of preβ-HDL particles. We determined macrophage cholesterol efflux to apoB-depleted plasma, which contains mature HDL, preβ-HDL particles and HDL regulatory proteins. ApoB-depleted plasma from AAA patients displayed an impaired ability to promote macrophage cholesterol efflux. Next, we replicated the experiments with AAA and control subjects derived from Danish cohort. Danish AAA patients also showed lower apoA-I levels and a defective HDL-mediated macrophage cholesterol efflux. Conclusions-AAA patients show impaired HDL-facilitated cholesterol removal from macrophages, which could be mechanistically linked to AAA. Visual Overview-An online visual overview is available for this article. 
C
irculating human HDL (high-density lipoproteins) include a highly complex and heterogeneous array of subpopulations that are continuously remodeled by plasma factors. 1 The ability of HDL particles to promote macrophage cholesterol efflux is the most extensively reported cardioprotective function associated with HDL.
2 ABC (ATP-binding cassette) A1 mediates cholesterol efflux to lipid-poor preβ-HDL and small HDL particles, 3 whereas another ABC transporter, ABCG1, facilitates cholesterol efflux to large-HDL particles. 4 In 2 human trials, the stimulation of the HDL-dependent cholesterol efflux from J774.A1 macrophage cells mediated by the ABCA1 has been found to be inversely associated with the incidence of atherothrombotic cardiovascular disease events. 5, 6 Two recent meta-analysis have demonstrated a potential role of lipoproteins in the pathogenesis of abdominal aortic aneurysm (AAA). 7, 8 We have previously reported in an epidemiological study that HDL cholesterol levels in AAA patients are lower than in patients with aortoiliac occlusive disease. 9 HDL cholesterol levels also predicted aneurysmal growth rate in a population-based prospective cohort study of AAA detected by mass screening. 9 However, HDL cholesterol levels do not necessarily reflect the functional dynamics of HDL to promote macrophage cholesterol efflux. 1 Macrophage infiltration, cholesterol accumulation, and ensuing cholesterol crystals are usually present in the human AAA wall. 10, 11 Moreover, LXR (liver X receptor) α and ABCA1 mRNA and protein levels were decreased in the AAA media compared with the normal media layer, pointing to possible deregulation of the cholesterol efflux mechanism in AAA. 11 In the present study, we have evaluated the composition of circulating HDL and their potential for promoting macrophage cholesterol efflux in AAA patients and normolipidemic control subjects.
Materials and Methods

Data Sharing
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Study Design and Participants
Initially, we randomly selected 20 AAA patients (aortic size >50 mm, confirmed with abdominal ultrasound) and normolipidemic control subjects (aortic size <30 mm) originating from Spain. Samples were obtained from the biobank of Fundación Jimenez Diaz. A second experiment with AAA patients and control subjects from the Danish cohort and matched with similar age and statin use was conducted to replicate and validate the main findings obtained from the Spanish cohort. Samples were derived from the VIVA trial (Viborg Vascular; URL: http://www.clinicaltrials.gov. Unique identifier: NCT00662480). The study was performed in accordance with the ethical principles set forth in the Declaration of Helsinki and approved by the institutional review committee of each Institution; the subjects studied gave informed consent.
Lipid, Lipoprotein Apolipoprotein Analyses
Plasma total cholesterol, triglycerides, and apoA-I were determined enzymatically and by an immunoturbidimetric assay, respectively, using commercial kits adapted to a COBAS 501c autoanalyzer (Roche Diagnostics). HDL cholesterol levels were measured in plasma obtained after precipitation of apoB-containing lipoprotein particles with phosphotungstic acid and magnesium ions (Roche Diagnostics). LDL (low-density lipoprotein) cholesterol levels were calculated with the Friedewald equation. Total HDL was isolated by sequential ultracentrifugation at density 1.063 to 1.21 kg/L, and lipids and apoA-I were determined as described above. Free cholesterol and phospholipids were evaluated with reagents from Wako Diagnostics. The amount of apoA-I in preβ-HDL particles was quantified with 2-dimensional crossed immunoelectrophoresis in individual plasma samples and in the plasma samples incubated for 6 hours at 37°C in the presence of a lecithin-cholesterol acyltransferase (LCAT) inhibitor (1 mmol/L iodoacetate). 14 LCAT activity was measured using the lipoproteins of plasma as substrate and expressed as molar esterification rates. 15 Alternatively, LCAT activity was measured with a radiometric method using radiolabeled reconstituted apoA-I-discoidal HDL particles as substrate and measuring the amount of radiolabeled cholesterol esters generated as described in more detail earlier. 16 
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Lipid Transfer Proteins and Enzymes
Cholesterol Efflux Assays
The cholesterol efflux capacity of apoB-depleted plasma samples (equivalent to 5% of plasma) was determined by using J774.A1 [ 3 H]-cholesterol-labeled mouse macrophages. 17 After 4 hours of incubation in the presence of apoB-depleted plasma, efflux of cholesterol was determined and expressed as [
. Spanish and Danish samples were assayed in duplicate in 2 independent batches by using 6-well plates. In each experiment, some AAA cases and control samples were always included in the same plate to minimize the effects of intra-plate variation. This experiment was also performed under experimental settings, which stimulated mainly ABCA1-dependent cholesterol efflux by treating the cells with 0.3 mmol/L cyclic adenosine monophosphate or, alternatively, stimulated concerted ABCA1/ ABCG1-dependent efflux pathways by treating the cells with 2 µmol/L T0901317 compound, a well-known LXR agonist.
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Statistical Analyses
Data are presented as mean±SEM for continuous variables and as frequencies and percentages for categorical variables. Fisher exact test was used to compare the categorical data between groups. The normality of the data was analyzed using the Kolmogorov-Smirnov test. The student unpaired t test was used to compare the continuous variables. Correlations between variables were analyzed using Pearson correlation analysis. Multivariate logistic regression models were analyzed to explore the association between efflux and AAA taking into account potential confounders, such as age, statins, HDL cholesterol, LDL cholesterol, apoA-I, preβ-HDL apoA-I levels, and triglycerides. The statistical software R (http://www.r-project.org) and GraphPad Prism 5.0 software (GraphPad, San Diego, CA) were used to perform all statistical analyses. A P value of <0.05 was considered to represent a significant difference in all the analyses.
Results
Defective Preβ-HDL Formation and HDL-Mediated Macrophage Cholesterol Efflux in Spanish Patients With AAA
Clinical characteristics of the Spanish cohort are shown in Table 1 . The AAA patients in the Spanish cohort showed lower plasma levels of HDL cholesterol and apoA-I, which were concomitant with low triglyceride and LDL cholesterol levels (Table 1) . Basal levels of preβ-HDL particles were 3-fold lower in AAA patients, and were kept at very low levels, even on incubation of plasma at 37°C in the presence of an LCAT inhibitor, as compared with the control group (Table 1) . This incubation approach measures plasma potential to generate preβ-HDL. However, the activities of the main HDL metabolism associated lipid transfer proteins and enzymes (PLTP, CETP, and LCAT) were similar in both groups (Table 1) . Pearson correlation test did not show any association between these plasma HDL remodeling proteins and preβ-HDL levels (r=−0.13, −0.28, and −0.08 for PLTP, CETP, and LCAT, respectively; P>0.05). Furthermore, the analysis of mature α-mobile HDL composition only revealed (Table 1) . Also, the inflammatory CRP (C-reactive protein) levels were similar in AAA patients and controls (4.27±1.36 versus 3.48±0.66 mg/L; P=0.609). Next, we determined macrophage cholesterol efflux to apoB-depleted plasma, which contains mature HDL, preβ-HDL particles, and HDL regulatory proteins, thereby permitting optimal HDL remodeling and cholesterol flux to HDL particles. ApoB-depleted plasma from Spanish AAA patients displayed an impaired ability to promote macrophage cholesterol efflux (Table 1 ). These differences were also observed under experimental settings, which stimulated mainly ABCA1-dependent cholesterol efflux (14.23±0.51% in controls versus 10.80±0.62% in AAA patients; P<0.001) or that, alternatively, stimulated concerted expression of ABCA1/ ABCG1 (25.29±0.56% in controls versus 21.39±1.00% in AAA patients; P=0.002).
A potential limitation of the study in the Spanish cohort was the increased age of AAA patients together with the higher percentage of patients under statin treatment. However, an inverse association between cholesterol efflux and AAA was observed, even after adjusting by age and statin intake (P=0.011).
Danish AAA Patients Show Impaired Macrophage Cholesterol Efflux
To validate/replicate the association of cholesterol efflux and preβ-HDL levels with AAA, a new experimental setup was conducted with AAA and control subjects derived from Danish cohort matched with similar age and statin use ( Table 2) . Danish AAA patients also showed lower LDL cholesterol and apoA-I levels, but HDL cholesterol levels were similar in both groups. Preβ-HDL particles levels tended to be lower in Danish AAA patients; however, this trend did not reach statistical significance (Table 2 ). More importantly, Danish AAA patients showed impaired macrophage cholesterol efflux (Table 2) , thereby emphasizing that this major HDL cardioprotective function was altered independently of HDL cholesterol levels, age, and statin use.
We also evaluated different multivariate logistic regression models to take into account potential confounders. An inverse association between cholesterol efflux and AAA was observed, even after adjusting for age, statin use and lipid, apoA-I, and lipoprotein levels (P≤0.016 for all logistic regression models). 
Discussion
Human AAA wall is characterized by the presence of cholesterol crystals and macrophage infiltration. 10, 18 Cholesterol crystals could promote AAA dilation and growth towards rupture by inducing smooth muscle cell death and an immuneinflammatory response. The presence of cholesterol crystals has been associated with a decrease in smooth muscle cell density in atherosclerotic plaques, suggesting a link between smooth muscle cell death and cholesterol crystals formation. 19 Cholesterol crystals also induce inflammasome activation, 20 and this has been shown to be involved in the development of experimental AAA. 21, 22 Furthermore, cholesterol accumulation as a result of an impaired cholesterol efflux sensitizes macrophages to a more proinflammatory state. 23 Two experimental studies have raised the concept that injecting reconstituted HDL, consisting of native apoA-I and phospholipids, or the apoA-I mimetic peptide D4F have potential to reduce AAA. 9, 24 Infusion of reconstituted HDL or D4F increase preβ-HDL levels and promote macrophage cholesterol efflux, 25, 26 thereby indicating that HDL-mediated macrophage cholesterol efflux could attenuate AAA progression. In the present study, we show, for the first time to our knowledge, that HDL from AAA patients has an impaired ability for promoting cholesterol efflux from macrophages.
We previously reported that plasma apoA-I levels were lower in AAA patients compared with those of healthy subjects. 9, 27 In the latter report, the percentage of small α-mobile HDL particles was moderately but significantly lower in AAA patients than in control subjects. These small HDL particles represented <10% of the total HDL pool of particles and the percentage of intermediate and large α-mobile HDL did not differ between the 2 groups. 27 These findings are in line with these new results in AAA patients with large AAA diameter (aortic diameter >50 mm) in which the amount of nascent preβ-HDL particles was low, but only moderate changes were found in the mature α-mobile HDL particles. The lack of association among the plasma factors involved in HDL remodeling and preβ-HDL particle levels in AAA patients indicates that the low preβ-HDL levels may be rather attributable to an impaired de novo formation of preβ-HDL or an enhanced clearance of lipid-free apoA-I, thereby reducing the potential to form apoA-I-containing mature α-mobile HDL. Also, it is possible that some inherent particle properties of HDL of AAA patients that is not detected based on major HDL component analysis attenuate particle interconversion to preβ-HDL. This view needs further verification.
Defects in macrophage cholesterol efflux in both Spanish and Danish AAA patients was even higher than what we recently found in Spanish familial hypercholesterolemic patients without any treatment. 28 However, we did not find any correlation between macrophage cholesterol efflux and AAA diameter in AAA patients. Because we only included AAA patients with large aortic diameter in this study, the narrower distribution of values could likely contribute to the loss of this correlation between AAA diameter and macrophage cholesterol efflux. Further studies are needed to establish the association between HDL-mediated macrophage cholesterol efflux and AAA presence and progression in larger cohorts.
In conclusion, the present study shows that AAA patients have low levels of plasma apoA-I and preβ-HDL particles and impaired macrophage cholesterol efflux. This major HDL functional alteration in AAA patients could be mechanistically linked to AAA.
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